Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001596770-16-000128
Filing Date
2016-03-28
Accepted
2016-03-28 17:06:54
Documents
1

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G 3-28-16 schedule13g.htm SC 13G 425806
  Complete submission text file 0001596770-16-000128.txt   427330
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-44055 | Film No.: 161532872
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 530 FIFTH AVENUE 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE 22ND FLOOR NEW YORK NY 10036 650-475-3734
VENROCK HEALTHCARE CAPITAL PARTNERS LP (Filed by) CIK: 0001458177 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SC 13G